Axentis Pharma AG

Axentis Pharma AG is a Swiss-based pharmaceutical company focused on value-added anti-infectives in combination with novel inhalation devices. Following the entrance of a License Agreement with a Japanese partner, Axentis Pharma engaged in the development of AX-TOBRA, a liposome-based drug-device combination to combat chronic lung diseases and respiratory disorders, especially cystic fibrosis. AX-TOBRA received Orphan Designations from EU-EMA and US-FDA. To protect Axentis Pharma against loss and damage from malversations caused by its Japanese partner, Axentis Pharma initiated arbitration proceedings in Tokyo, and, ultimately, won a final and binding Arbitration Award against its former partner. The award was issued by the Japan Commercial Arbitration Association (JCAA) in Tokyo in August 2013. Currently, Axentis Pharma is seeking to enforce the Arbitration Award through judicial remedies.

C-Suite On Deck

Responsive image

Feature market insights and perspectives from top C-Level executives, elite technology influencers and thought leaders from your company here. This signature initiative has garnered immense support...

Contact Us

Events

Related News

BUSINESS INSIGHTS

ABCELLERA AND EMPIRICO EXPAND STRATEGIC MULTI-TARGET ANTIBODY DISCOVERY COLLABORATION

AbCellera | May 04, 2022

news image

AbCellera and Empirico Inc. announced today that they have expanded their strategic multi-target discovery collaboration, which leverages Empirico’s Precision Insights PlatformTM to discover genetically validated drug targets and AbCellera’s technology to identify lead candidate antibodies against those targets. Following the rapid progress of their first collaborative program, which identified a lead candidate against an undisclosed G protein-coupled receptor target in less than 12 ...

Read More

PHARMACY MARKET

THE MCQUADE CENTER FOR STRATEGIC RESEARCH AND DEVELOPMENT AND MINDSET PHARMA COLLABORATE TO DEVELOP PSYCHEDELIC MEDICINES

McQuade | January 06, 2022

news image

The McQuade Center for Strategic Research and Development, LLC, a member of the global Otsuka family of pharmaceutical companies, and Mindset Pharma Inc. announce a collaboration that will support the development of psychedelic medicines. MSRD has made a strategic investment to support the discovery and development of novel chemical entity assets of Mindset, a drug discovery and development company focused on creating optimized and patentable next-generation psychedelic medicines to treat neurol...

Read More

RESEARCH

HEMOGENYX PHARMACEUTICALS AND SELEXIS SA WILL ADVANCE HEMOGENYX’S ACUTE MYELOID LEUKEMIA (AML) CDX BISPECIFIC ANTIBODY TO HUMAN TRIALS

Hemogenyx Pharmaceuticals plc | January 13, 2022

news image

Hemogenyx Pharmaceuticals plc the biopharmaceutical group developing new therapies and treatments for blood diseases, and Selexis SA, a JSR Life Sciences company, have signed a service agreement to develop the cell line for Hemogenyx’s CDX bispecific antibody for the treatment of acute myeloid leukemia (AML). Under the agreement, Hemogenyx will leverage Selexis’ proprietary SUREtechnology Platform™, a suite of cell line development tools and technologies that significantly redu...

Read More

BUSINESS INSIGHTS

CRESCITA SIGNS EXCLUSIVE 8-COUNTRY LICENSING AGREEMENT WITH EGIS PHARMACEUTICALS FOR PLIAGLIS®

Crescita Therapeutics | December 13, 2021

news image

Crescita Therapeutics Inc. a growth-oriented, innovation-driven Canadian commercial dermatology company, is pleased to announce that it has signed an exclusive commercialization and supply agreement with Egis Pharmaceuticals PLC a leading generic pharmaceutical company in Central Eastern Europe for the rights to Pliaglis in eight countries comprising Hungary, Bulgaria, Czech Republic, Slovakia, Poland, Russia, Latvia and Lithuania. Under the terms of the agreement, Crescita will r...

Read More
news image

BUSINESS INSIGHTS

ABCELLERA AND EMPIRICO EXPAND STRATEGIC MULTI-TARGET ANTIBODY DISCOVERY COLLABORATION

AbCellera | May 04, 2022

AbCellera and Empirico Inc. announced today that they have expanded their strategic multi-target discovery collaboration, which leverages Empirico’s Precision Insights PlatformTM to discover genetically validated drug targets and AbCellera’s technology to identify lead candidate antibodies against those targets. Following the rapid progress of their first collaborative program, which identified a lead candidate against an undisclosed G protein-coupled receptor target in less than 12 ...

Read More
news image

PHARMACY MARKET

THE MCQUADE CENTER FOR STRATEGIC RESEARCH AND DEVELOPMENT AND MINDSET PHARMA COLLABORATE TO DEVELOP PSYCHEDELIC MEDICINES

McQuade | January 06, 2022

The McQuade Center for Strategic Research and Development, LLC, a member of the global Otsuka family of pharmaceutical companies, and Mindset Pharma Inc. announce a collaboration that will support the development of psychedelic medicines. MSRD has made a strategic investment to support the discovery and development of novel chemical entity assets of Mindset, a drug discovery and development company focused on creating optimized and patentable next-generation psychedelic medicines to treat neurol...

Read More
news image

RESEARCH

HEMOGENYX PHARMACEUTICALS AND SELEXIS SA WILL ADVANCE HEMOGENYX’S ACUTE MYELOID LEUKEMIA (AML) CDX BISPECIFIC ANTIBODY TO HUMAN TRIALS

Hemogenyx Pharmaceuticals plc | January 13, 2022

Hemogenyx Pharmaceuticals plc the biopharmaceutical group developing new therapies and treatments for blood diseases, and Selexis SA, a JSR Life Sciences company, have signed a service agreement to develop the cell line for Hemogenyx’s CDX bispecific antibody for the treatment of acute myeloid leukemia (AML). Under the agreement, Hemogenyx will leverage Selexis’ proprietary SUREtechnology Platform™, a suite of cell line development tools and technologies that significantly redu...

Read More
news image

BUSINESS INSIGHTS

CRESCITA SIGNS EXCLUSIVE 8-COUNTRY LICENSING AGREEMENT WITH EGIS PHARMACEUTICALS FOR PLIAGLIS®

Crescita Therapeutics | December 13, 2021

Crescita Therapeutics Inc. a growth-oriented, innovation-driven Canadian commercial dermatology company, is pleased to announce that it has signed an exclusive commercialization and supply agreement with Egis Pharmaceuticals PLC a leading generic pharmaceutical company in Central Eastern Europe for the rights to Pliaglis in eight countries comprising Hungary, Bulgaria, Czech Republic, Slovakia, Poland, Russia, Latvia and Lithuania. Under the terms of the agreement, Crescita will r...

Read More